NCT03729804 2026-03-04
(COBRA)
University of Chicago
Phase 3 Active not recruiting
Clinical Trials
34 trialsNCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
NCT00572169 2026-02-05
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
University of Arkansas
Phase 3 Active not recruiting
NCT03617731 2026-02-03
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
University of Heidelberg Medical Center
Phase 3 Active not recruiting
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT07285239 2025-12-16
PrE1005
PrECOG, LLC.
Phase 3 Not yet recruiting
NCT01241708 2025-09-17
(Mel/MelVel)
Hackensack Meridian Health
Phase 3 Completed
NCT00734877 2025-06-29
TT4B
University of Arkansas
Phase 3 Active not recruiting
NCT03643276 2025-04-06
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
University Hospital Schleswig-Holstein
Phase 3 Recruiting
NCT01788020 2024-05-13
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
University of Ulm
Phase 3 Completed
NCT01685814 2023-04-27
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg University Hospital
Phase 3 Unknown
NCT02495922 2021-09-10
GMMG-HD6
University of Heidelberg Medical Center
Phase 3 Completed
NCT01146834 2019-12-27
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
Weill Medical College of Cornell University
Phase 3 Completed
NCT01191060 2019-04-18
IFM/DFCI2009
University Hospital, Toulouse
Phase 3 Completed
NCT02489500 2018-09-10
VelRand
Boston Medical Center
Phase 3 Terminated
NCT01554852 2018-06-11
Myeloma XI
University of Leeds
Phase 3 Unknown
NCT00574080 2017-11-20
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
University of Arkansas
Phase 3 Terminated
NCT00657553 2017-11-20
2007-77
University of Arkansas
Phase 3 Terminated
NCT03345303 2017-11-17
Bortezomib in Intrahepatic Cholangiocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital
Phase 3 Unknown
NCT01916252 2017-09-27
GEM2012MENOS65
PETHEMA Foundation
Phase 3 Completed
NCT01449344 2017-03-07
(R-HAD)
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT01324596 2016-04-15
REMoDL-B
University Hospital Southampton NHS Foundation Trust
Phase 3 Completed
NCT01530594 2016-02-25
Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma
King Faisal Specialist Hospital & Research Center
Phase 3 Completed
NCT01971658 2015-10-07
IFM2013-04
Nantes University Hospital
Phase 3 Completed
NCT00111748 2015-10-06
UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
University of Arkansas
Phase 3 Completed
NCT01998503 2013-11-29
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Nanjing University School of Medicine
Phase 3 Completed
NCT01134484 2012-07-20
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase 3 Unknown
NCT00573391 2011-08-12
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
University of Arkansas
Phase 3 Terminated
NCT00602511 2011-02-09
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
Nordic Myeloma Study Group
Phase 3 Completed
NCT00093028 2010-07-02
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
University of Arkansas
Phase 3 Completed
NCT00417911 2010-06-22
Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients
Nordic Myeloma Study Group
Phase 3 Completed
NCT00461747 2009-09-18
GEM05MENOS65
PETHEMA Foundation
Phase 3 Completed
NCT00200681 2009-02-05
IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma
Nantes University Hospital
Phase 3 Completed